Pharmacological treatment of obesity: Present status

International Journal of Obesity

Volumn 23, Issue , 1999, Pages 47-53

  Scheen, A J ^a   Lefebvre P J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Anorectic drugs; Appetite; Energy expenditure; Nutrient partitioning; Risk factors; Weight loss

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; AMFEPRAMONE; AMPHETAMINE; AMYLIN DERIVATIVE; ANOREXIGENIC AGENT; ANTIDEPRESSANT AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; CAFFEINE; DEXFENFLURAMINE; ENZYME INHIBITOR; EPHEDRINE; FENFLURAMINE; FLUOXETINE; GLUCAGON LIKE PEPTIDE 1; MAZINDOL; METFORMIN; NORADRENALIN UPTAKE INHIBITOR; PHENMETRAZINE; PHENTERMINE; PHENYLPROPANOLAMINE; SIBUTRAMINE; TESTOSTERONE; TETRAHYDROLIPSTATIN; THYROID HORMONE; TRIACYLGLYCEROL LIPASE;

AMINE TRANSPORT; BLOOD PRESSURE; CHRONIC DISEASE; CONFERENCE PAPER; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG ABUSE; DRUG DEPENDENCE; DRUG LEGISLATION; ENERGY EXPENDITURE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART RATE VARIABILITY; HUMAN; HYPERTENSION; HYPOLIPEMIA; LEAN BODY WEIGHT; LIPID ABSORPTION; METABOLIC DISORDER; METABOLISM; NERVE STIMULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK FACTOR; TREMOR; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; CLINICAL TRIALS; DIGESTION; EATING; ENERGY INTAKE; ENERGY METABOLISM; HUMANS; OBESITY; WEIGHT LOSS;

EID: 0344334027     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0800795     Document Type: Article

References (57)

1. Scheen AJ; Desaive C; Lefèbvre PJ. Therapy for obesity-today and tomorrow. Bailliere’s Clin Endocrinol Metab 1994; 8: 705-727.
2. Rosenbaum Ms Leibel RL; Hirsch J. Obesity. N Engl J Med 1997; 337: 396-405.
3. Garrow JS. Treatment of obesity. Lancet 1992; 340: 409-413.
4. Bray GA (1998). Pharmacological treatment of obesity. In: GA Bray, C Bouchard, WPT James (eds). Handbook of obesity. M Dekker: New York, Basel, Hong Kong, 953-975.
5. Bray GA; Ryan DH. Drugs used in the treatment of obesity. Diabetes Rev 1997; 5: 83-103.
6. Finer N. Present and future pharmacological approaches. Br Med Bull 1997; 53: 409-432.
7. Atkinson RL. Use of drugs in the treatment of obesity. Ann Rev Nutr 1997; 17: 383-403.
8. North American Association for the Study of Obesity. Guidelines for the approval and use of drugs to treat obesity. Obes Res 1995; 3: 473-478.
9. Silverstone T. Appetite suppressants. A review. Drugs 1992; 820-836.
10. Abenhaim L; Moride Y Brenot F Rich S Benichou J Kurz X Higenbottam T Oakley C Wouters E Aubier M Simon-neau G; Bégaud B; for the International Primary Pulmonary Hypertension Study Group. Appetite-suppressant drugs and the risk of pulmonary hypertension. N Engl J Med 1996; 335: 609-616.
11. Connolly HM; Crary JL; McGoon MD; Hensrud DD; Edwards BS’ Edwards WDS Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 581-588.
12. Davis R’ Faulds D. Dexfenfluramine. An updated review of its therapeutic use in the management of obesity. Drugs 1996; 52: 696-724.
13. Guy-Grand B. Clinical studies with dexfenfluramine: from past to future. Obes Res 1995; 3 (Suppl 4): 491S-496S.
14. Fuller RWS Wong DT. Fluoxetine: a serotonergic appetite suppressant drug. Drug Develop Res 1988; 17: 1-15.
15. Goldstein DJ; Rampey AH; Roback PJ; Wilson MG Hamilton SH Sayler MES Tollefson GD. Efficacy and safety of longterm fluoxetine treatment of obesity-Maximizing success. Obes Res 1995; 3 (Suppl 4): 481S-490S.
16. Atkinson RL; Blank RC; Loper JF; Schumacher D; Lutes RA. Combined treatment of obesity. Obes Res 1995; 3 (Suppl 4): 497-500S.
17. Weintraub M. Long-term weight control (parts 1-7)-The National-Heart-Lung-and-Blood-Institute funded multimodal intervention study. Clin Pharm 1992; 51: 581-641.
18. Weintraub M, Rubio A, Golik A, Byrne L. Sibutramine dose ranging, efficacy study. Clin Pharm 1991; 50: 330-337.
19. Ryan DH, Kaiser P, Bray GA. Sibutramine: a novel new agent for obesity treatment. Obes Res 1995; 3 (Suppl 4): 553S-559S.
20. Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res 1996; 4: 263-270.
21. Dulloo AG (Ed). Ephedrine, xanthines, aspirin and other thermogenic drugs to assist the dietary management ofobesity. Int J Obes 1993; 17 (Suppl 1): S1-S83.
22. Howe R. Beta3-adrenergic agonists. Drugs Future 1993; 18: 529-549.
23. Himms-Hagen J, Danforth E Jr. The potential role of b3 adrenoceptor agonists in the treatment of obesity and diabetes. Curr Opin Endocrinol Diab 1996; 3: 59-65.
24. Scheen AJ, Lefèbvre PJ. Pharmacological treatment of the obese diabetic patient. Diab Metab 1993; 19: 547-559.
25. Astrup A, Breum L, Toubro S. Pharmacological and clinical studies of ephedrine and other thermogenic agonists. Obes Res1995; 3 (Suppl 4): 537S-540S.
26. Liu YL, Toubro S, Astrup A, Stock MJ. Contribution of beta3-adrenoceptor activation to ephedrine-induced thermogenesis in humans. Int J Obes 1995; 19: 678-685.
27. Yen TT. Antiobesity and antidiabetic b-agonists: lessons learned and questions to be answered. Obes Res 1994; 2: 472-480.
28. Pietri-Rouxel F, Strosberg AD. Pharmacological characteristics and species related variations of b3-adrenergic receptors. Fundam Clin Pharmacol 1995; 9: 211-218.
29. Arner P. The b3-adrenergic receptor-A cause and cure of obesity? N Engl J Med 1995; 333: 382-383.
30. Scheen AJ. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s: achievements and future developments. Drugs 1997; 54: 355-368.
31. Balfour JA, McTavish D. Acarbose-an update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993; 46: 1025-1054.
32. William-Olsson T. a-glucosidase inhibition in obesity. Acta MedScand 1986; 219 (Suppl 706) 1-39.
33. Guerciolini R. Mode of action of orlistat. Int J Obes 1997; 21 (Suppl 3): S12-S23.
34. McNeely W, Benfield P. Orlistat. Drugs 1998; 56: 241-249.
35. Drent ML, Larsson I, William-Olsson T, Quaade F, Czubayko F, von Bergmann K, Strobel W, Sjostrom L, van der Veen EA. Orlistat (Ro18-0647), a lipase inhibitor, in the treatment of obesity: a multiple dose study. Int J Obes 1995; 19: 221-226.
36. Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49: 721-749.
37. Bray GA. Evaluation of drugs for treating obesity. Obes Res1995; 3 (Suppl 4): 425S-434S.
38. Scoville BA. Review of amphetamine-like drugs by the Food and Drug Administration: clinical data and value judgements. In: Bray GA (ed). Obesity in perspective: Proceedings of the Fogarty Conference, 1975. Washington DC: United States Government. 441-443.
39. Goldstein DJ, Potvin JH. Long-term weight loss: the effect of pharmacologic agents. Am J Clin Nutr 1994; 60: 647-657.
40. Guy-Grand B, Crepaldi G, Lefebvre P, Apfelbaum M, Gries A, Turner P. International trial of long-term dexfenfluramine in obesity. Lancet 1989; 2: 1142-1145.
41. Mathus-Vliegen EM, van de Voorde K, Kok AM, Res AM. Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behavior. J Int Med 1992; 232: 119-127.
42. Andersen T, Astrup A, Quaade F. Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: a randomized clinical trial. Int J Obes 1992; 16: 35-40.
43. Pfohl M, Luft D, Blomberg I, Schmolling R-M. Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine. Int J Obes 1994; 18: 391-395.
44. Darga LL, Carroll-Michals L, Borsford SJ, Lucas CP. Fluoxetine’s effect on weight loss in obese subjects. Am J Clin Nutr1991; 54: 321-325.
45. Goldstein DJ, Rampey AH, Enas GG, Potvin JH, Fuldzinski LA, Levine LR. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes 1994; 18: 129-135.
46. Rottiers R et al. A randomised double-blind, placebo-controlled, parallel group, trial with diethylpropion resinate in the treatment of obese patients. 1998, submitted.
47. Jones SP, Smith IG, Kelly F, Gray JA. Long-term weight loss with sibutramine (Abstract). Int J Obes 1995; 19 (Suppl 2): 41.
48. Finer N, for the UK Orlistat Group. Weight reduction with orlistat and effects on risk factors: a 1-year UK study (Abstract). Int J Obes 1997; 21 (Suppl 2): S31.
49. Foreyt J. A 2-year multicenter study of the effects of orlistat (XenicalR) on weight loss and disease risk factors (Abstract). Obes Res 1997; 5 (Suppl 1): 53S.
50. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HPF, Krempf M, for the European Multicentre Orlistat Study Group. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167-173.
51. Scheen AJ. Anti-obesity drugs in the treatment of NIDDM. Int Diab Monitor 1997; 9: 1-8.
52. Scheen AJ. Aggressive weight reduction treatment in the management of type 2 diabetes. Diab Metab 1998; 24: 116-123.
53. Scheen AJ, Paolisso G, Salvatore T, Lefèbvre PJ. Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine. Diabetes Care 1991; 14: 325-332.
54. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998; 21: 1288-1294.
55. Kolanowski J, Younis LT, Vanbutsele R, Detry J-M. Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients. Eur J Clin Pharmacol 1992; 42: 599-606.
56. Flechtner-Mors M, Ditschuneit HH, Yip I, Adler G. Blood pressure and plasma norepinephrine responses to dexfenflur-amine in obese postmenopausal women. Am J Clin Nutr 1998; 67: 611-615.
57. Tonstad S, Pometta D, Erkelens DW, Ose L, Moccetti T, Schouten JA, Golay A, Reitsma J, DelBufalo A, Pasotti E, van der Wal P. The effects of gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol 1994; 46: 405-410.